Natera/$NTRA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
$NTRA
Sector
Primary listing
Employees
4,429
Headquarters
Website
Natera Metrics
BasicAdvanced
$31B
-
-$2.29
1.64
-
Price and volume
Market cap
$31B
Beta
1.64
52-week high
$246.90
52-week low
$125.38
Average daily volume
1.5M
Financial strength
Current ratio
3.274
Quick ratio
3.006
Long term debt to equity
8.336
Total debt to equity
14.752
Interest coverage (TTM)
-80.52%
Profitability
EBITDA (TTM)
-317.999
Gross margin (TTM)
63.66%
Net profit margin (TTM)
-14.61%
Operating margin (TTM)
-16.62%
Effective tax rate (TTM)
0.23%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-12.89%
Return on equity (TTM)
-29.02%
Valuation
Price to revenue (TTM)
14.38
Price to book
24.77
Price to tangible book (TTM)
24.77
Price to free cash flow (TTM)
325.322
Free cash flow yield (TTM)
0.31%
Free cash flow per share (TTM)
0.693
Growth
Revenue change (TTM)
38.17%
Earnings per share change (TTM)
29.83%
3-year revenue growth (CAGR)
39.72%
10-year revenue growth (CAGR)
27.44%
3-year earnings per share growth (CAGR)
-26.14%
10-year earnings per share growth (CAGR)
-2.70%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Natera News
AllArticlesVideos
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
Business Wire·2 days ago
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
Business Wire·6 days ago
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Natera stock?
Natera (NTRA) has a market cap of $31B as of December 18, 2025.
What is the P/E ratio for Natera stock?
The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of December 18, 2025.
Does Natera stock pay dividends?
No, Natera (NTRA) stock does not pay dividends to its shareholders as of December 18, 2025.
When is the next Natera dividend payment date?
Natera (NTRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Natera?
Natera (NTRA) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.